Scopus BioPharma Stock Forecast, Price & News

Scopus BioPharma (NASDAQ:SCPS) Frequently Asked Questions

Is Scopus BioPharma a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scopus BioPharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Scopus BioPharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SCPS, but not buy additional shares or sell existing shares.
View analyst ratings for Scopus BioPharma or view top-rated stocks.

What stocks does MarketBeat like better than Scopus BioPharma?

Wall Street analysts have given Scopus BioPharma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Scopus BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Scopus BioPharma?

Scopus BioPharma saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 119,100 shares, an increase of 88.2% from the September 15th total of 63,300 shares. Based on an average trading volume of 448,600 shares, the short-interest ratio is presently 0.3 days. Currently, 2.7% of the shares of the stock are sold short.
View Scopus BioPharma's Short Interest.

What price target have analysts set for SCPS?

1 brokers have issued 12 month target prices for Scopus BioPharma's shares. Their forecasts range from $20.00 to $20.00. On average, they expect Scopus BioPharma's stock price to reach $20.00 in the next year. This suggests a possible upside of 401.3% from the stock's current price.
View analysts' price targets for Scopus BioPharma or view top-rated stocks among Wall Street analysts.

Who are Scopus BioPharma's key executives?

Scopus BioPharma's management team includes the following people:

• Mr. Robert J. Gibson, Vice Chairman, Sec. & Treasurer
• Mr. Ashish Pradip Sanghrajka, Pres & Director (Age 47, Pay $600k)
• Mr. Ira Scott Greenspan, Sr. Advisor & Director (Age 62, Pay $180k)
• Mr. Daniel J. Politzer C.F.A., CFO & COO (Age 52)
• Mr. David Silberg, Sr. Advisor (Age 72)

Who are some of Scopus BioPharma's key competitors?

Some companies that are related to Scopus BioPharma include DFP Healthcare Acquisitions (DFPH), CRH Medical (CRHM), Viemed Healthcare (VMD), Eargo (EAR), Candel Therapeutics (CADL), Syros Pharmaceuticals (SYRS), Millendo Therapeutics (MLND), AquaBounty Technologies (AQB), Portage Biotech (PRTG), CymaBay Therapeutics (CBAY), Checkpoint Therapeutics (CKPT), Orchard Therapeutics (ORTX), Alpine Immune Sciences (ALPN), Celcuity (CELC) and Theratechnologies (THERF).
View all of SCPS's competitors.

What is Scopus BioPharma's stock symbol?

Scopus BioPharma trades on the NASDAQ under the ticker symbol "SCPS."

How do I buy shares of Scopus BioPharma?

Shares of SCPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scopus BioPharma's stock price today?

One share of SCPS stock can currently be purchased for approximately $3.99.

How much money does Scopus BioPharma make?

Scopus BioPharma has a market capitalization of $72.20 million.

How many employees does Scopus BioPharma have?

Scopus BioPharma employs 1 workers across the globe.

What is Scopus BioPharma's official website?

The official website for Scopus BioPharma is scopusbiopharma.com.